Acute Lymphoblastic Leukemia (ALL)

Prof. Dr. Fevzi ALTUNTAS

Yıldırım Beyazıt Medical School

Department of Internal Medicine

Division of Hematology

Term-IV, 2020, Ankara

Acute Leukemia

ALL

- Define :
  - Heterogeneous group of malignant disorders which is characterized by uncontrolled clonal and accumulation of blasts cells in the bone marrow and body tissues
- Sudden onset
- If left untreated is fatal within a few weeks or months
- Incidence 2-3/100,000/year

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Acute Leukaemogenesis

- **Develop as a result of a genetic alteration within single cell in the bone marrow**
  - **a*)*** ***Epidemiological evidence :***
    - **1. Hereditary Factors**
      - **Fanconi's anaemia**
      - **Down's syndrome**
      - **Ataxia telangiectasia**
    - **2. Radiation, Chemicals and Drugs**
    - **3. Virus related Leukemias**
      - **Retrovirus : HTLV 1 & EBV**

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Acute Leukaemogenesis

b) Molecular Evidence

- ***Oncogenes*** **:**
  - **Gene that code for proteins involved in cell proliferation or differentiation**
- ***Tumour Suppressor Genes :***
  - **Genes that protect a cell from one step on the path to cancer.**
  - **Genes that normally prevent cell division.**
- **Changes within oncogene or suppressor genes are necessary to cause malignant transformation.**

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Acute Leukaemogenesis

Oncogene can be activated by :

· **chromosomal translocation**


· **point mutations**

· **inactivation**

- In general, several genes have to be altered to effect neoplastic transformation.

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Acute Leukemia



Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Pathophysiology

- Acute leukemia cause morbidity and mortality through:
  A. **Deficiency in blood cell number and function**
  B. **Invasion of vital organs**
  C. **Systemic disturbances by metabolic imbalance**

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Pathophysiology

A. Deficiency in blood cell number or function

i. Infection

- Most common cause of death
- Due to impairment of phagocytic function and neutropenia

ii. Hemorrhage

- Due to thrombocytopenia or 2^{o} DIC or liver disease

iii. Anemia

- Normochromic-normocytic
- Severity of anemia reflects severity of disease
- Due to ineffective erythropoiesis

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Pathophysiology

B. Invasion of vital organs

- Vary according to subtype

i. Hyperleukocytosis

- Cause increase in blood viscosity
- Predispose to microthrombi or acute bleeding
- Organ involve : brain, lung, eyes
- Injudicious used of packed cell transfusion precipitate hyperviscosity

ii. Leucostatic tumour

- Rare
- Blast cell lodge in vascular system forming macroscopic pseudotumour – erode vessel wall cause bleeding

iii. Hidden site relapse

- Testes and meninges (CNS)

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


Pathophysiology

C. Metabolic imbalance

- Due to disease or treatment
  - Hyponatremia vasopressin-like subst. by myeloblast
  - Hypokalemia due to lysozyme release by myeloblast
  - Hyperuricaemia- spont lysis of leukemic blast release purines into plasma
  - Tumor lysis syndrome- hyperkalemia, hyperphosphatemia, hypocalcaemia, hyperuricaemia

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


Pathogenesis of tumor lysis syndrome



Mosby items and derived items © 2006 by Mosby, Inc.

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Pathophysiology




Mosby items and derived items © 2006 by Mosby, Inc.

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Classification


Acute lymphoblastic leukemia (ALL)



Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Acute Lymphoblastic Leukemia (ALL)

- Cancer of the blood affecting the WBC known as *LYMPHOCYTES.*
- Commonest in the age 2-10 years.
- Peak at 3-4 years.
- Incidence decreases with age, and a secondary rise after 40 years.
- In children - most common malignant disease
  - **85% of childhood leukemia**




Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Acute Lymphoblastic Leukemia


Specific manifestation:

- Bone pain, arthritis
- Lymphadenopathy
- Hepatosplenomegaly
- **Mediastinal mass (T-ALL)**
- **Testicular swelling**
- **Meningeal syndrome**



Acute Lymphoblastic Leukemia


ALL



Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


Acute Lymphoblastic Leukemia

ALL



Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Acute Lymphoblastic Leukemia



	Children	Adults
Physical Examination		
Fever	50-60	35-55
Bleeding	40-50	30-35
Bone pain	20-30	20-30
LAP	15-20	10-15
Hepatomegaly	50-60	30-35
Splenomegaly	50-60	50-60
Testicular enlargement	1	<1
Laboratory Findings		
Leukocyte count (*109/L)		
<10	50	40
>100	10	15
Hb (g/dL)		
<8	50	30
>10	20	50
Platelet count (*109/L)		
<50	50	50
>100	30	25


ALL: Investigations

1. *Complete blood count*

- **Anemia**
  - **normochromic, normocytic**
- **WBC <1.0x10^9/l to >200x10^9/L,**
  - **Neutropenia and**
  - **full blast cells**
- **Thrombocytopenia <10x10^9/L.**


	Children	Adults
Physical Examination		
Fever	50-60	35-55
Bleeding	40-50	30-35
Bone pain	20-30	20-30
LAP	15-20	10-15
Hepatomegaly	50-60	30-35
Splenomegaly	50-60	50-60
Testicular enlargement	1	<1
Laboratory Findings		
Leukocyte count (*109/L)		
<10	50	40
>100	10	15
Hb (g/dL)		
<8	50	30
>10	20	50
Platelet count (*109/L)		
<50	50	50
>100	30	25

Investigations



Blast-

Acute lymphoblastic leukemia




Blasts-


Acute myeloblastic leukemia

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

ALL: Investigations

- **ALL (Lymphoblast)**
  - **Blast size** : Small
  - **Cytoplasm**: Scant
  - **Chromatin**: Dense
  - **Nucleoli** : Indistinct
  - **Auer-rods**: Never present
- **AML (Myeloblast)**
  - Large
  - Moderate
  - Fine, Lacy
  - Prominent
  - Present in 50%





ALL: Investigations


2. Bone marrow aspiration


and trephine biopsy

- **confirm acute leukemia**

(blast ≥ 25% for ALL)

- **usually hypercellular**





© 2007 Terese Winslow
U.S. Govt. has certain rights

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


ALL: Investigations

3. Cytochemical staining

a) Peroxidase (MPO):

   a) Negative ALL

   b) Positive AML




Positive for myeloblast

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

ALL: Investigations

b) Periodic acid schiff (PAS)

- **Positive ALL**
- Negative AML




Block positive in ALL

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

ALL: Investigations

c) Acid phosphatase :

- **Focal positive = T-ALL**



Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

ALL: Investigations

4.Immunophenotyping

- **identify antigens present on the blast cells**
- **determine whether the leukaemia is lymphoid or myeloid (**especially important when cytochemical markers are negative. E.g : AML-M0)
- **differentiate T-ALL and B-ALL**

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

ALL: Investigations

4.Immunophenotyping

- Certain antigens have prognostic significance
- Rare cases of biphenotypic where both myeloid and lymphoid antigen are expressed on the same blast cells.
- Monoclonal antibodies (MoAb) are recognized under a cluster of differentiation (CD).
- **MONOCLONAL ANTIBODIES USED FOR CHARACTERISATION OF ALL.**

ALL : B-ALL CD10, CD 19, CD22

T-ALL CD3, CD7

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Differential diagnosis according to Immunophenotyping

ALL

The European Group for the Immunological Classification of Leukemias (EGIL) scoring system.[5]

Points	Myeloid	B-lineage	T-lineage
2	MPO	CD79a Cyt IgM Cyt CD22	CD3, cyt and surface TCR αβ TCR γδ
1	CD13 CD33 CD65	CD19 CD10 CD20	CD2 CD5 CD8 CD10
0.5	CD14 CD15 CD64 CD117	TdT CD24	TdT CD7 CD1a

Abbreviations: MPO, myeloperoxidase; TdT, terminal deoxynucleotidyl transferase; cyt, cytoplasmic; TCR, T-cell receptor.
≥ 2 points are required to assign a lineage.

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Classification according to *Immunophenotyping*

B-ALL

	TdT	CD19	CD79	CyCD22	CD10	CylgM	sIg	Sk/l
Pro-B	+	+	+	+	-	-	-	-
Common	+	+	+	+	+	-	-	-
Pre-B	+	+	+	+	+	+/-	-	-
B-Mature	-	+	+	+	-	-	+	+

Ig gene rearrangement

T-ALL

	TdT	CyCD3	CD7	CD2	CD5	CD1a	sCD3
Pro-T	+	+	+	-	-	-	-
Pre-T	+	+/-	+	+	+	-	-
T-Cortical	+	-	+	+	+	+	+/-
T-Mature	+/-	-	+	+	+	-	+

TCR gene rearrangement

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

ALL: Investigations

5. Cytogenetics and molecular studies

- detect abnormalities within the leukemic clone
- have diagnostic or prognostic value
  - E.g : the Philadelphia chromosome : the product of a translocation between chromosomes 9 and 22
    - very poor prognosis in ALL


Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

YILDIRIM BEYAZIT ÜNİVERSİTESİ 2010

Table 2. Main genetic abnormalities in ALL

Disease	Abnormality	Genes involved	Incidence	Molecular detection
B-ALL	t(9;22)(q34;q11)	BCR ABL	Adults: 30% Children: 3%	RT-PCR
	t(12;21)(p13;q22)	TEL AML1	Adults: <1% Children: 20%	RT-PCR
	t(4;11)(q21;q23)	MLL AF4	Adults: 5% Infants: 60%	RT-PCR
	t(1;19)(q23;p13)	E2A PBX1	5%	RT-PCR
	t(8;14)(q24;q32)	c-MYC IgH	1%	FISH
	t(17;19)(q22;p13)	E2A HLF	<1%	RT-PCR
	t(11;19)(q23;p13)	MLL ENL JAK1/2/3 mutations	<1% 10%	RT-PCR Sequencing
T-ALL	t(10;14)(q24;q11) t(7;10)(q34;q24	HOX11 TCR α/δ HOX11 TCR β	Adults: 31% Children: 7%	RT-PCR
	t(5;14)(q35;q32)	HOX11L2 TCR β	Adults: 13% Children: 20%	RT-PCR, FISH
	t(1;14)(p32;q11)	TAL1 TCR α/δ	1-3%	RT-PCR
	Normal 1p32	SIL TAL1	9-30%	RT-PCR
	inv(7)(p15q34), t(7;7)	HOXA genes TCR β	5%	FISH, RT-PCR
	t(10;11)(p13;q14-21)	CALM AF10	10%	FISH
	t(9;9)(q34;q34)	NUP214 ABL1	6%	FISH
	t(9;14)(q34;q34)	EML1 ABL1	<1%	FISH
	NOTCH1 mutations	NOTCH1	50%	Sequencing
	JAK1 mutations	JAK1	18%	Sequencing

Philadelphia chromosome




Mosby items and derived items © 2006 by Mosby, Inc.

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

ALL: Others Investigations

6. ***Biochemical screening***
   - **Leucocyte count very high - renal impairment and hyperuricemia**
7. ***Chest radiography***
   - **Mediastinal mass - present in up to 70% of patients with T –ALL**
8. ***Lumbar puncture*** **(LP)S**
   - **Initial staging investigation to detect leu cells in the cerebrospinal fluid, indicating involvement of the CNS**
   - Done in acute lymphoblastic leukemia



Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


ALL: Classification

Morphological classification[1]	
L1	Small uniform blast cells with scanty cytoplasm
L2	Large heterogeneous blast cells with nucleoli and low nuclear–cytoplasmic ratio
L3	Basophilic vacuolated blast cells
Immunological classification	
B-lineage ALL	
Early pre-B	
Pre-B ALL	
B-cell	
T-lineage ALL	
Early	
Cortical	
Mature	

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

FAB-Acute Lymphoblastic Leukemia

	Morphology	L_1	L_2	L_3
1	Size of blast	Small	Large heterogeneous	Large homogenous
2	Cytoplasm	Scanty	Moderate	Moderate, intensely basophilic
3	N/C Ratio	High	Lower	Lower
4	Cytoplasmic vacuoles	+/-	+/-	Prominent
5	Nuclear membrane	Regular	Irregular with clef ting	Regular
6	Nucleoli	Invisible / indistinct	Prominent 1-2	Prominent 1-2





Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


FAB-Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL)*

- **L-1** **85%**
- L-2 14%
- L-3 (Burkitt's) 1% childhood







Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

FAB CRITICISM

1- It dose not include
- Immunophenotyping
- Cytogentics
- Molecular characteristics

2- immunological subtype of ALL

3-biphenotypic leukemia

4- Limited relevance to therapeutic or prognostic implications.

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

2016 WHO classification

B-lymphoblastic leukemia/lymphoma

- B-lymphoblastic leukemia/lymphoma, NOS
- B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities
- B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1
- B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged
- B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1
- B-lymphoblastic leukemia/lymphoma with hyperdiploidy
- B-lymphoblastic leukemia/lymphoma with hypodiploidy
- B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH
- B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1
- Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like
- Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP21

T-lymphoblastic leukemia/lymphoma

- Provisional entity: Early T-cell precursor lymphoblastic leukemia
- Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymphoma

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

Classification of ALL(WHO)

Immunologic subtype	% of cases	FAB subtype	Cytogenetic abnormalites
Pre B ALL	75	L1,L2	t(9;22),t(4;11) t(1;19)
Tcell ALL	20	L1,L2	14q11 or 7q34
Mature Bcell ALL(burkitt leukemia)	5	L3	t(8;14)

The most common type is precursor B ALL


Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

ALL: Poor Prognostic Factors

	Standart	Poor
Age	• Young (<35)	• Elderly (>35)
Cytogenetic	• Hyperdiploid	• **Ph+,** • **t(4;11)**
WBC	• <30.000/µL	• >30.000 /µL (B-ALL) • >100.000/µL (T-ALL)
Immunophenotype	• Tymic-ALL	• Pro-B-ALL • Early T-ALL • Mature T-ALL
Time to CR	• <2-4 weeks	• >2-4 weeks
MRD	• Negative	• Positive

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

RİSK BASED THERAPY



Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

ALL-Treatment

Pediatric-Inspired Chemotherapy Regimens: Generic Components	
Induction (4 weeks)	Prednisone, vincristine, PEG-asparaginase, daunorubicin
Consolidation (8 weeks)	Cyclophosphamide, cytarabine, mercaptopurine, vincristine, PEG-asparaginase
Interim Maintenance (8 weeks)	High-dose methotrexate, mercaptopurine, vincristine
Delayed Intensification (8 weeks)	Dexamethasone, vincristine, PEG-asparaginase, doxorubicin, cyclophosphamide, cytarabine, thioguanine
Maintenance (2 years)	Mercaptopurine, methotrexate, vincristine, dexamethasone

Note: Intrathecal methotrexate also given intermittently throughout

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com

ALL-Treatment

Chemotherapy Regimens for Adult ALL

	Induction	Consolidation	CR	Overall Survival
CALGB 8811[7]	D, Pred, V, C, L-Asp	C, SC AraC, 6-MP, V, L-Asp, Dox, MTX, 6-TG, Dex	84%	50% (3-year)
Linker[6]	D, Pred, V, L-Asp	V, Pred, D, L-Asp, 6-MP, AraC, E, MTX	93%	47% (5-year)
HyperCVAD[9]	C, V, Dox, Dex alternating with MTX, AraC	See "Induction"	92%	38% (5-year)
UKALL/ECOG 2993[8]	D, Pred, V, C, AraC, 6-MP	AraC, E, V, Dex, D, C, 6-TG	91%	38% (5-year)

6-MP = 6-mercaptopurine; 6-TG = 6-thioguanine; ALL = acute lymphoblastic leukemia; AraC = cytarabine; C = cylophosphamide; CALGB = Cancer and Leukemia Group B; CR = complete remission; D = daunorubicin, Dex = dexamethasone; Dox = doxorubicin; E = etoposide; ECOG = Eastern Cooperative Oncology Group; L-Asp = L-asparaginase; MTX = methotrexate; Pred = prednisone; SC = subcutaneous; UKALL = United Kingdom ALL; V = vincristine.

Steroid and vincristine are the most important drugs for treatment of ALL

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


ALL-Treatment- TKI

Subtype	Chemotherapy regimen	Imatinib dosing				Results (%)			
		Induction (mg/d)	Consolidation (mg/d)	Mantenance (mg/d)	No	CR	Relapse	DFS (at y)	Survival (at y)
Adults									
Thomas el al	Hyper-CVAD	C (400)	C (400)	C (400)	39	92	14	83(3)	55 (3)
Yanada el al	JALSG ALL202	C (600)	A (600)	C (600)	80	96	26	60 (1) 51 (2)	76 (1) 58 (2)
Lee et al	Modified from Linker	C (600)	C (400)	C (400)	20	95	32	62 (2)	59 (2)
Wassmann et al	GMALL Alternating Concurrent	 None None	 A (400/600) C (600)	 NR NR	 47 45	 NA NA	 NR NR	 52 (2) 61 (2)	 36 (2) 43 (2)
de Labarthe el al	GRAAPH-2003	None	C (600)	NR	45	96	19	51 (1.5)	65 (1.5)
Ottmann et el al	GMALL Chemotherapy Imatinib	 None Only (600)	 C (600) C (600)	 C (600) C (600)	 28 27	 96 50	 41 54	 29 (1.5) 57 (1.5)	 35 (1.5) 41 (1.5)

C= concurrent; A= alternating; NR= not reported; NA= not applicable; JALSG = Japan Adult Leukemia Study Group; GMALL= German Multi-Centre Acute Lymphoblastic Leukemia; hyper-CVAD= fractionated cyclophosphamide, vincristine, doxorubicine, dexamethasone; GRAAPH= Group for Research on Adult Acute Lymphoblastic Leukemia; GIMEMA= Gruppo Italiano Malattie Ematologiche dell'Adulto; GRAALL=Group for Research in Adult Acute Lymphoblastic Leukemia; Pred= prednisone

TKI (Imatinib/Dasatinib) is another important drug in patient with Ph(+)

Prof. Dr. FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com


ALL
BM biopsy to confirm Dx
Age
16-40
41-60
≥ 60
ALL-13-01
• Continue as per ALL-13-01
• Ph+ ALL are not eligible
• Risk stratification and SCT as per standard criteria
If Ph+ ALL:
Add Imatinib (600mg po daily) Initial therapy on ALL-89-01
ALL 89-01 Modified>50
• No L-Asparaginase
• No WBI
Modified ALL 89-01
• No L-Asparaginase / No WBI
• Delete Cyclophosphamide Day 28 Induction II
• Add Imatinib if ph⊕
• t(9;22) ⊕ Cytogentics FISH or PCR, add Imatinib (600mg po daily)
Day 21-24 BM
CR
Yes
No
• Study Protocol
• Palliation
SCT Candidate
Yes
No
Consider RIC Allo (BMT 06-03 or BMT 04-01A)
• Consolidation I,II ± Imatinib
• Maintenance (6MP+MTX) ± TKI
Day 21-24 BM
Status
Refractory
PR
CR1
• Extend Dauno 60mg/m² IV x 2days
• Vincrishine 1.4mg/m² day 28,35
• Prednisone 60mg/m² po till day 42
*Risk Stratification
standard
*high
• ALL 89-01 Induction II
• Consolidation + Maintenance
*High Risk
• Ph⊕ by cytogenetics, FISH, or PCR
• t(4;11), t(1,19)
• Low hypodiploid / near triploidy
• Complex karyotype
• Failure to achieve CR after Induction Chemo (Day 21-29 Marrow)
• WBC>50x10⁹/L B-cell, WBC>100x10⁹/L T-cell
• BCR/ABL numerical abnormalities by FISH
Day 42 BM
CR
No
Yes
SCT Candidate
No
Yes
Salvage VP/CY (AL 91-02)
CR
No
Yes
• No L-Asparaginase
• Donor Search
• Induction II
• No Prophylactic WBI
SCT Candidate
Yes
No
• Study Protocol
• Palliation
Allo SCT Candidate MR|UD Allo in CR1
Consolidation as per ALL 89-01 protocol
Patients with high risk are candidate for Allo-SCT
Unofficial document if printed. Please refer to the following web address for up to date information: http://www.healthcareprofessionals.leukemiabmtprogram.com

www.drfevzialtuntas.com
faltuntas@hotmail.com

Prof. Dr.
FEVZİ ALTUNTAŞ
www.drfevzialtuntas.com